



TORII PHARMACEUTICAL CO., LTD.

SHIONOGI Group Company

Tokyo, April 27, 2026

**FOR IMMEDIATE RELEASE**

**Announcement Regarding Absorption-Type Merger of Torii  
by Shionogi & Co., Ltd.**

With respect to an absorption-type merger with Shionogi & Co., Ltd. (“Shionogi”) as the surviving company and Torii Pharmaceutical Co., Ltd. (“Torii”) as the absorbed company (the “Merger”), regarding which Torii had announced its support for the basic policy in Torii’s press release dated February 20, 2026, titled “[Announcement of Decision on Basic Policy Regarding Absorption-Type Merger of Torii by Shionogi & Co., Ltd.](#),” Torii hereby announces that, today, an absorption-type merger agreement has been entered into by and between Shionogi and Torii with an effective date of April 1, 2027.

Since Torii became a wholly owned subsidiary of Shionogi as of September 1, 2025, both companies have been working to build a stronger system for delivering our respective core products to a broader patient population by leveraging each company’s distinct strengths and by expanding and reinforcing our medical information and promotion activities. Torii believes that the realization of the Merger will further accelerate these initiatives and enable us to make even greater contributions to healthcare.

Please see the announcement from Shionogi at the following link:

Shionogi’s Press Release (External Link)

["Notice Regarding the Absorption-Type Merger of Torii Pharmaceutical Co., Ltd., a Wholly Owned Subsidiary"](#)

Contact for Torii Pharmaceutical Co., Ltd.:  
Corporate Planning Department  
(Public Relations)  
Torii Pharmaceutical Co., Ltd.  
Tokyo: +81-3-3231-6814  
E-mail: [webmaster@torii.co.jp](mailto:webmaster@torii.co.jp)